U.S. markets open in 9 minutes
  • S&P Futures

    3,373.75
    +21.75 (+0.65%)
     
  • Dow Futures

    27,806.00
    +142.00 (+0.51%)
     
  • Nasdaq Futures

    11,551.50
    +144.25 (+1.26%)
     
  • Russell 2000 Futures

    1,513.70
    +9.30 (+0.62%)
     
  • Crude Oil

    39.18
    -1.04 (-2.59%)
     
  • Gold

    1,909.60
    +14.10 (+0.74%)
     
  • Silver

    23.75
    +0.26 (+1.11%)
     
  • EUR/USD

    1.1747
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    0.7140
    +0.0370 (+5.47%)
     
  • Vix

    25.84
    -0.43 (-1.64%)
     
  • GBP/USD

    1.2911
    -0.0010 (-0.08%)
     
  • USD/JPY

    105.6750
    +0.2450 (+0.23%)
     
  • BTC-USD

    10,896.21
    +100.18 (+0.93%)
     
  • CMC Crypto 200

    234.73
    +13.34 (+6.03%)
     
  • FTSE 100

    5,876.94
    +10.84 (+0.18%)
     
  • Nikkei 225

    23,185.12
    0.00 (0.00%)
     

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020

Avid Bioservices, Inc

TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2021 on September 1, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).  Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 27 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

CONTACT: Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com